95 related articles for article (PubMed ID: 36527482)
1. Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients.
Freiberger SN; Holzmann D; Morand GB; Hüllner M; Levesque MP; Dummer R; Koelzer VH; Rupp NJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5645-5653. PubMed ID: 36527482
[TBL] [Abstract][Full Text] [Related]
2. Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab.
Krueger O; Eisenburger R; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Theurer S; Brodin B; Schadendorf D; Ugurel S
Front Immunol; 2024; 15():1369190. PubMed ID: 38807589
[TBL] [Abstract][Full Text] [Related]
3. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.
Horowitch B; Lee DY; Ding M; Martinez-Morilla S; Aung TN; Ouerghi F; Wang X; Wei W; Damsky W; Sznol M; Kluger H; Rimm DL; Ishizuka JJ
Clin Cancer Res; 2023 Aug; 29(15):2908-2918. PubMed ID: 37233452
[TBL] [Abstract][Full Text] [Related]
4. A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ; Verheijden RJ; van Diest PJ; Blokx WAM; El-Sharouni MA; Verhoeff JJC; Leiner T; van den Eertwegh AJM; de Groot JWB; van Not OJ; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Stevense-den Boer MAM; Boers-Sonderen MJ; Kapiteijn E; Suijkerbuijk KPM; Elias SG
Int J Cancer; 2024 May; 154(10):1760-1771. PubMed ID: 38296842
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma.
Ueda S; Miyahara Y; Nagata Y; Sato E; Shiraishi T; Harada N; Ikeda H; Shiku H; Kageyama S
Oncotarget; 2018 Nov; 9(89):35997-36011. PubMed ID: 30542513
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review.
Heng JS; Kim JM; Jones DK; Stoessel KM; Weiss SA; Sznol M; Kluger HM; Walter SD; Silverstein NA; Pointdujour-Lim R
BMJ Open Ophthalmol; 2022; 7(1):e000889. PubMed ID: 35047671
[TBL] [Abstract][Full Text] [Related]
7. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Campbell KM; Amouzgar M; Pfeiffer SM; Howes TR; Medina E; Travers M; Steiner G; Weber JS; Wolchok JD; Larkin J; Hodi FS; Boffo S; Salvador L; Tenney D; Tang T; Thompson MA; Spencer CN; Wells DK; Ribas A
Cancer Cell; 2023 Apr; 41(4):791-806.e4. PubMed ID: 37037616
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
Tian J; Quek C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673829
[TBL] [Abstract][Full Text] [Related]
9. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker.
Amrane K; Le Meur C; Besse B; Hemon P; Le Noac'h P; Pradier O; Berthou C; Abgral R; Uguen A
Front Immunol; 2023; 14():1285895. PubMed ID: 38299143
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma.
Lau D; McLean MA; Priest AN; Gill AB; Scott F; Patterson I; Carmo B; Riemer F; Kaggie JD; Frary A; Milne D; Booth C; Lewis A; Sulikowski M; Brown L; Lapointe JM; Aloj L; Graves MJ; Brindle KM; Corrie PG; Gallagher FA
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34561275
[TBL] [Abstract][Full Text] [Related]
12. Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
Pabla S; Seager RJ; Van Roey E; Gao S; Hoefer C; Nesline MK; DePietro P; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Schoenborn M; Zhang S; Klein R; Glenn ST; Conroy JM
Biomark Res; 2021 Jul; 9(1):56. PubMed ID: 34233760
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Ressler JM; Tomasich E; Hatziioannou T; Ringl H; Heller G; Silmbrod R; Gottmann L; Starzer AM; Zila N; Tschandl P; Hoeller C; Preusser M; Berghoff AS
Target Oncol; 2024 Mar; 19(2):263-275. PubMed ID: 38401029
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?
Splendiani E; Besharat ZM; Covre A; Maio M; Di Giacomo AM; Ferretti E
Pharmacol Ther; 2024 Apr; 256():108613. PubMed ID: 38367867
[TBL] [Abstract][Full Text] [Related]
15. Research progress in effects of MAGE-A family on gastric cancer.
Jia Q; Xian X; Li Y; Mu J; DU Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 48(2):260-267. PubMed ID: 36999473
[TBL] [Abstract][Full Text] [Related]
16. Multi-cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma.
Yan J; Deng L; Yu J; Wu X; Wang S; Cang S
Clin Transl Med; 2023 Nov; 13(11):e1478. PubMed ID: 37987157
[No Abstract] [Full Text] [Related]
17. Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.
Riaz N; Havel JJ; Kendall SM; Makarov V; Walsh LA; Desrichard A; Weinhold N; Chan TA
Nat Genet; 2016 Nov; 48(11):1327-1329. PubMed ID: 27668655
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report.
Ong CV; Samlowski W
Front Oncol; 2024; 14():1301424. PubMed ID: 38549929
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma.
Stephens MR; Asdourian MS; Jacoby TV; Shah N; Thompson LL; Otto T; Semenov YR; Reynolds KL; Sullivan RJ; Foreman RK; Chen ST
J Am Acad Dermatol; 2023 Jul; 89(1):140-142. PubMed ID: 36806644
[No Abstract] [Full Text] [Related]
20. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Freeman SS; Sade-Feldman M; Kim J; Stewart C; Gonye ALK; Ravi A; Arniella MB; Gushterova I; LaSalle TJ; Blaum EM; Yizhak K; Frederick DT; Sharova T; Leshchiner I; Elagina L; Spiro OG; Livitz D; Rosebrock D; Aguet F; Carrot-Zhang J; Ha G; Lin Z; Chen JH; Barzily-Rokni M; Hammond MR; Vitzthum von Eckstaedt HC; Blackmon SM; Jiao YJ; Gabriel S; Lawrence DP; Duncan LM; Stemmer-Rachamimov AO; Wargo JA; Flaherty KT; Sullivan RJ; Boland GM; Meyerson M; Getz G; Hacohen N
Cell Rep Med; 2022 Feb; 3(2):100500. PubMed ID: 35243413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
